title: A controlled trial of idebenone in Huntington's disease.
abstract: One hundred patients with clinically diagnosed Huntington's disease (HD) were randomized to either idebenone, an antioxidant and enhancer of oxidative metabolism, or placebo, in a 1-year, double-blind, parallel-group study aimed at slowing the rate of progression of the disease. Ninety-one patients completed the study. There were no significant differences between groups on the primary outcome measures of the Huntington's Disease Activities of Daily Living Scale (ADL-an index of functional status) and the Quantified Neurologic Examination (QNE). Sample size calculations based on progression of the ADL and QNE in this study group revealed that a larger study group is necessary to detect any differences less than an almost complete halting of the disease. This argues for multicenter efforts for future therapeutic trials in HD.
authors.affiliation: Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
authors.forename: N G
authors.initials: NG
authors.lastname: Ranen
authors.forename: C E
authors.initials: CE
authors.lastname: Peyser
authors.forename: J T
authors.initials: JT
authors.lastname: Coyle
authors.forename: F W
authors.initials: FW
authors.lastname: Bylsma
authors.forename: M
authors.initials: M
authors.lastname: Sherr
authors.forename: L
authors.initials: L
authors.lastname: Day
authors.forename: M F
authors.initials: MF
authors.lastname: Folstein
authors.forename: J
authors.initials: J
authors.lastname: Brandt
authors.forename: C A
authors.initials: CA
authors.lastname: Ross
authors.forename: S E
authors.initials: SE
authors.lastname: Folstein
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use*; D016227:Benzoquinones / Q000494:pharmacology* / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010919:Placebos; D017470:Receptors, Glutamate / Q000187:drug effects; D016896:Treatment Outcome; D014451:Ubiquinone / Q000031:analogs & derivatives
chemical_list: D000975:Antioxidants; D016227:Benzoquinones; D010919:Placebos; D017470:Receptors, Glutamate; D014451:Ubiquinone; C036619:idebenone